Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Dec;5(2):169-182.
doi: 10.1007/s40120-016-0048-2. Epub 2016 Jul 13.

Pregnancy Experience: Nonclinical Studies and Pregnancy Outcomes in the Daclizumab Clinical Study Program

Ralf Gold  1 , Dusan Stefoski  2 , Krzysztof Selmaj  3 , Eva Havrdova  4 , Christopher Hurst  5 , Joan Holman  6 , Belen Tornesi  6 , Surekha Akella  7 , Peter McCroskery  5
Affiliations

Pregnancy Experience: Nonclinical Studies and Pregnancy Outcomes in the Daclizumab Clinical Study Program

Ralf Gold et al. Neurol Ther. 2016 Dec.

Abstract

Introduction: Multiple sclerosis (MS) is more common in women and can occur during childbearing years; thus, information on outcomes following exposure to MS therapy during pregnancy is important. No formal studies of daclizumab have been conducted in pregnant women. Here, we report available nonclinical and clinical data on pregnancy outcomes from the daclizumab clinical study program.

Methods: Reproductive and developmental toxicity studies were conducted in cynomolgus monkeys. Reports of pregnancies that occurred during the daclizumab clinical study program through March 9, 2015 were collated and summarized. In the event of pregnancy, daclizumab was discontinued and safety monitoring continued.

Results: Studies in cynomolgus monkeys showed no daclizumab-related effects on maternal well-being, embryo-fetal development, indirect fertility end points, and pre- and postnatal development and growth. Across the clinical study program, 38 pregnancies were reported in 36 daclizumab-exposed women (on treatment ≤6 months from last dose); 20 resulted in live births and four (11%) in spontaneous abortions or miscarriages. One congenital heart defect (complex transposition of great vessels) occurred in one live birth (considered unrelated to daclizumab); daclizumab had been discontinued and intramuscular interferon beta-1a and lisinopril were used at conception. Eight women had an elective termination, two had an ectopic pregnancy, and two were lost to follow-up; two pregnancy outcomes are pending. Six additional pregnancies occurred in five women >6 months after their last daclizumab dose; in one additional pregnancy, exposure was unknown.

Conclusion: Spontaneous abortion rate in daclizumab-exposed women was consistent with early pregnancy loss in the general population (12%-26%). Data on pregnancies exposed to daclizumab do not suggest an increased risk of adverse fetal or maternal outcomes, although the numbers are too small for definitive conclusions. CLINICALTRIALS.

Gov identifiers: NCT00390221, NCT01064401, NCT01462318, NCT00870740, NCT01051349, and NCT01797965.

Funding: Biogen and AbbVie Biotherapeutics Inc.

Keywords: Clinical trials; Daclizumab; Multiple sclerosis; Pregnancy; Teratogenicity.

PubMed Disclaimer

References

    1. Ghezzi A, Annovazzi P, Portaccio E, Cesari E, Amato MP. Current recommendations for multiple sclerosis treatment in pregnancy and puerperium. Expert Rev Clin Immunol. 2013;9:683–691. doi: 10.1586/1744666X.2013.811046. - DOI - PubMed
    1. Lu E, Wang BW, Guimond C, et al. Safety of disease-modifying drugs for multiple sclerosis in pregnancy: current challenges and future considerations for effective pharmacovigilance. Expert Rev Neurother. 2013;13:251–260. doi: 10.1586/ern.13.12. - DOI - PubMed
    1. Bielekova B. Daclizumab therapy for multiple sclerosis. Neurotherapeutics. 2013;10:55–67. doi: 10.1007/s13311-012-0147-4. - DOI - PMC - PubMed
    1. Wiendl H, Gross CC. Modulation of IL-2Rα with daclizumab for treatment of multiple sclerosis. Nat Rev Neurol. 2013;9:394–404. doi: 10.1038/nrneurol.2013.95. - DOI - PubMed
    1. Airas L, Saraste M, Rinta S, Elovaara I, Huang YH, Wiendl H, Finnish Multiple Sclerosis and Pregnancy Study Group Immunoregulatory factors in multiple sclerosis patients during and after pregnancy: relevance of natural killer cells. Clin Exp Immunol. 2008;151:235–243. doi: 10.1111/j.1365-2249.2007.03555.x. - DOI - PMC - PubMed

Associated data

LinkOut - more resources